Wednesday, November 4, 2026
ExploreSearch
Via News
Via News Knowledge File

Eli Lilly and Company

organization80% conf.·synced Nov 4, 2026

Pharmaceutical company with gene therapy licensing deal with REGENXBIO

60
sourced metrics
1308
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
1409.38USD
Nov 3, 2026reference only
Price 52 Week High
1417.54USD
Nov 3, 2026reference only
Market Cap
1326729820270USD
Nov 3, 2026reference only
Price 52 Week Low
851.21USD
Nov 3, 2026reference only
Stock Return Ytd
30.5%
Nov 3, 2026reference only
Shares Outstanding
941357065.0shares
Aug 3, 2026reference only
Net Income
7095000000.0USD
Jun 30, 2026reference only
Eps
7.94USD_per_share
Jun 30, 2026reference only
Revenue
22974000000.0USD
Jun 30, 2026reference only
Cash
8950000000.0USD
Jun 30, 2026reference only
Total Assets
142283000000.0USD
Jun 30, 2026reference only
Stockholders Equity
33879000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
3268000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
5333000000.0USD
Mar 31, 2026reference only

Stated objectives

Obtain U.S. regulatory approval for Inluriyo in combination with abemaciclib for ESR1-mutated MBC

source
stated

Advance LY4064809/STX-478 from Phase 1/2 to Phase 3 trial for PIK3CA-mutant HR+, HER2- advanced breast cancer

source
stated

Demonstrate overall survival benefit, progression-free survival, and time to chemotherapy improvements in EMBER-3 trial for ESR1-mutated breast cancer

source
stated

Show sustained IDFS/DRFS improvements and OS prolongation in monarchE trial across nodal status subgroups

source
stated

Translate biologic conviction into meaningful progress by addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K

source
stated

Demonstrate non-inferiority of pirtobrutinib versus ibrutinib on overall response rate in CLL/SLL patients

source
target: non-inferiority on ORR stated

Complete formal PFS analysis testing for superiority of pirtobrutinib

source
target: superiority on PFS stated

Verify and describe clinical benefit of Jaypirca in confirmatory trials to maintain accelerated approval status

source
target: clinical benefit verification stated

Demonstrate pirtobrutinib's potential role across treatment settings and B-cell malignancies through development program

source
stated

Receive regulatory approvals for pirtobrutinib in earlier disease settings to expand treatment options for patients

source
target: regulatory approval by 2026-01-01 00:00:00stated

Relationship graph · 1308 connections

Developed by
526
Competes with
205
Employs
86
Covered by
58
acquired by
54
regulates
46
headquartered in
45
located in
27
board member of
Dave Ricks

Via News coverage

NVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Pharma Outsources R&D to AI Platforms
June 19, 2026
NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies
May 27, 2026
NVIDIA's BioNeMo Becomes Global Drug Discovery's Default AI Infrastructure as Big Pharma Cedes Biology to Specialists
May 21, 2026
NVIDIA's BioNeMo Becomes Global Drug Discovery Infrastructure as Eli Lilly and Thermo Fisher Join Platform
May 16, 2026
NVIDIA BioNeMo Platform Secures Partnerships with Eli Lilly, Thermo Fisher for AI Drug Discovery
April 21, 2026
NVIDIA's BioNeMo Platform Powers $1.3 Trillion Pharma Industry's AI Pivot Across Three Continents
April 18, 2026
NVIDIA's BioNeMo Platform Reaches Eli Lilly and Thermo Fisher in Global Pharma AI Push
April 13, 2026
NVIDIA's BioNeMo Platform Deployed by Eli Lilly, Thermo Fisher, Six Biotech Firms for AI Drug Discovery
April 11, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Moves Into Devices, Security and Platforms: Physical AI Data, On-Device Compute and Agent Governance Drive a Late-October Product Wave
In late October 2026, vendors across hardware, enterprise software and security launched products built around AI moving out of the cloud and into devices, workflows and physical systems. Examples include NVIDIA RTX Spark laptops with Adobe, ASUS and Windows support for local and hybrid AI, and Harvest Praxis and Encord on embodied or physical AI. Enterprise software and security vendors (Salesforce–Braze, Fortinet, ServiceNow, Cisco, Intuit) are consolidating AI-driven customer data, adding inline AI security and agent governance, and embedding AI in financial and accounting workflows. The finance link is indirect: it rests on M&A, fintech-adjacent AI tooling and the capital flowing into physical AI. No regulatory driver appears in the facts.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,548 source documents archived
Query this data → isubstrate.com